Rigel Pharmaceuticals Inc. (RIGL)

2.14
NASDAQ : Health Technology
Prev Close 2.14
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.96 / 4.71
Avg Volume 2.07M
Exchange NASDAQ
Shares Outstanding 166.64M
Market Cap 366.61M
EPS -0.60
P/E Ratio 73.33
Div & Yield N.A. (N.A)

Latest News

Insiders Now Seeing Red With RIGL At New 52-Week Low

Insiders Now Seeing Red With RIGL At New 52-Week Low

In trading on Tuesday, shares of Rigel Pharmaceuticals Inc touched a new 52-week low of $2.56/share. That's a $2.15 share price drop, or -45.65% decline from the 52-week high of $4.71 set back on 01/23/2018.

RIGL: Insiders Vs. Shorts

RIGL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Rigel Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 11.07 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Rigel Announces Third Quarter 2018 Financial Results And Provides Company Update

Rigel Announces Third Quarter 2018 Financial Results And Provides Company Update

Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million

Rigel To Present Data On Fostamatinib In Three Presentations At The 60th American Society Of Hematology Annual Meeting & Exposition

Rigel To Present Data On Fostamatinib In Three Presentations At The 60th American Society Of Hematology Annual Meeting & Exposition

Data related to fostamatinib accepted for oral presentation and two poster presentations

Rigel Pharmaceuticals Enters Collaboration And License Agreement With Kissei Pharmaceutical Co., Ltd. To Develop And Commercialize TAVALISSE™ (fostamatinib Disodium Hexahydrate) In Japan And Other Asian Countries

Rigel Pharmaceuticals Enters Collaboration And License Agreement With Kissei Pharmaceutical Co., Ltd. To Develop And Commercialize TAVALISSE™ (fostamatinib Disodium Hexahydrate) In Japan And Other Asian Countries

- Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries

Rigel To Host Investor & Analyst Day In New York City On October 4, 2018

Rigel To Host Investor & Analyst Day In New York City On October 4, 2018

SOUTH SAN FRANCISCO, Calif., Sept.

Rigel To Present At The Cantor Global Healthcare Conference

Rigel To Present At The Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept.

Rigel To Present At The 20th Annual Global Investment Conference In New York City

Rigel To Present At The 20th Annual Global Investment Conference In New York City

SOUTH SAN FRANCISCO, Calif., Aug.

RIGL: Insiders Vs. Shorts

RIGL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 08/15/2018 settlement date, and Rigel Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.22 "days to cover" versus the median component at 5.05. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Rigel Announces Second Quarter 2018 Financial Results And Provides Company Update

Rigel Announces Second Quarter 2018 Financial Results And Provides Company Update

$1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate)

First Week Of RIGL March 2019 Options Trading

First Week Of RIGL March 2019 Options Trading

Investors in Rigel Pharmaceuticals Inc saw new options begin trading this week, for the March 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.89/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $2.50 strike, which has a bid at the time of this writing of 35 cents.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.87/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 50 cents.

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

The South San Francisco, Calif.-based firm said the U.S. Food and Drug Administration indicated that it does not plan to conduct an Oncology Drugs Advisory Committee meeting to discuss Rigel's new drug application for fostamatinib in chronic or persistent immune thrombocytopenia.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.85/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $2.50 strike, which has a bid at the time of this writing of 55 cents.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

TheStreet Quant Rating: D (Sell)